

Jing Medicine Technology (Shanghai) Ltd. is an innovation-driven biotech startup company focusing on turning cutting-edge science and technology into therapeutics. It was founded in early 2017 with USD \$20 million in Series A financing. Located on the campus of ShanghaiTech University (STU) in Pudong, the mission of the company is to incubate, translate and commercialize life science research accomplishments at STU. Jing Medicine is committed to the development of therapeutic monoclonal antibody and small molecule drugs for the unmet medical needs in oncology, immunology, and neurology. Several research projects currently in the preclinical stage have their own intellectual properties. A number of programs have formed domestic and international collaboration.

The R&D management team is composed of senior executives and scientists from the United States and China, with extensive experience in world class biotech and pharmaceutical companies. The company is a foreign joint venture with investors which have strong background and excellent investment track record in the biotech and pharmaceutical industries. Our current investors include Shanghai Alliance Investment Ltd. (SAIL), WuXi AppTec (Shanghai) Co., Ltd., ZL China Holding Two (ZAI Lab), and Shanghai Cenova Xinghe Venture Capital Center, L.P.

和径医药科技（上海）有限公司
地址：中国上海浦东新区海科路 99 号 6 号楼
邮编 201210 Tel: (86)21-60352900

Jing Medicine Technology (Shanghai) Ltd.
Building No. 6, First Floor, 99 Haike Road, Pudong,
Shanghai 201210, China Tel: (86)21-60352900